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The nucleus incertus (NI), a brainstem structure with diverse anatomical connections, is implicated in
anxiety, arousal, hippocampal theta modulation, and stress responses. It expresses a variety of neuro-
transmitters, neuropeptides and receptors such as 5-HT1A, D2 and CRF1 receptors. We hypothesized that
the NI may play a role in the neuropharmacology of buspirone, a clinical anxiolytic which is a 5-HT1A
receptor partial agonist and a D2 receptor antagonist. Several preclinical studies have reported a biphasic
anxiety-modulating effect of buspirone but the precise mechanism and structures underlying this effect
are not well-understood. The present study implicates the NI in the anxiogenic effects of a high dose of
buspirone. Systemic buspirone (3 mg/kg) induced anxiogenic effects in elevated plus maze, light-dark
box and open ﬁeld exploration paradigms in rats and strongly activated the NI, as reﬂected by c-Fos
expression. This anxiogenic effect was reproduced by direct infusion of buspirone (5 mg) into the NI, but
was abolished in NI-CRF-saporin-lesioned rats, indicating that the NI is present in neural circuits driving
anxiogenic behaviour. Pharmacological studies with NAD 299, a selective 5-HT1A antagonist, or quin-
pirole, a D2/D3 agonist, were conducted to examine the receptor system in the NI involved in this anx-
iogenic effect. Opposing the 5-HT1A agonism but not the D2 antagonism of buspirone in the NI attenuated
the anxiogenic effects of systemic buspirone. In conclusion, 5-HT1A receptors in the NI contribute to the
anxiogenic effect of an acute high dose of buspirone in rats and may be functionally relevant to physi-
ological anxiety.
© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Buspirone is an atypical anxiolytic highly prescribed for gener-
alized anxiety disorder (Apter and Allen,1999; Flint, 2005; Gale and
Millichamp, 2016; Goa and Ward, 1986). It is a 5-HT1A receptor
partial agonist and a D2-like receptor antagonist (Loane and Politis,
2012; Newman-Tancredi et al., 1998; Tunnicliff, 1991). Unlike the
benzodiazepines, the precise anxiolytic mechanism of buspirone
remains unclear with inconsistencies in anxiolytic effects observed
in the clinic and animal models of anxiety (Chessick et al., 2006). Itlogy, Yong Loo Lin School of
Y, Level 4, MD3, 16 Medical
we).
Ltd. This is an open access article uis noted from numerous reports that acute treatment of buspirone
in rodents causes an anxiolytic effect at a narrow, low dose range
that is highly variable across species and anxiety paradigms, while
an anxiogenic effect is evident at a wide, high dose range (Bradley
et al., 2011; Collinson and Dawson, 1997; de Oliveira Cito Mdo et al.,
2012; File and Andrews, 1991; Handley and McBlane, 1993;
Hestermann et al., 2014; Inagaki et al., 2010; Lim et al., 2008;
Moser, 1989; Paine et al., 2002; Shimada et al., 1995; Soderpalm
et al., 1989; Thompson et al., 2015; Varty et al., 2002). The anxio-
genic effect of buspirone is a clinical concern as it manifests in the
initial acute phase of chronic buspirone treatment regimens
(Chignon and Lepine, 1989; Liegghio et al., 1988; Newton et al.,
1986; Sinclair et al., 2009).
The complex receptor afﬁnity proﬁle of buspirone may underlie
its biphasic pharmacological effects (Tunnicliff, 1991). Buspirone
acts as a full agonist at the somatodendritic 5-HT1A autoreceptorsnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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consequentially decreasing the serotonin released in target struc-
tures and thus increasing ﬁring. This is thought to be at least partly
responsible for its anxiolytic effects (Carli et al., 1989; Hutson et al.,
1989; Sharp et al., 1989a, 1989b; Sprouse and Aghajanian, 1987;
Tunnicliff, 1991). However, buspirone also acts as an agonist at
the post-synaptic 5-HT1A receptors thus reducing neuronal ﬁring.
These opposing effects could be responsible for the biphasic
anxiety-modulating effects buspirone displays (Andrews et al.,
1994; File et al., 1996; Hodges et al., 1987). Some pharmacological
interaction studies conducted with WAY 100635, a 5-HT1A antag-
onist, indicated that the anxiogenic effects and anxiolytic effects of
buspirone are mediated by its interaction with the D2-like and 5-
HT1A receptor systems, respectively (Collinson and Dawson,
1997). The above conclusions ignore the considerable afﬁnity and
efﬁcacy of WAY-100635 at D2-like receptors (Chemel et al., 2006;
Johansson et al., 1997). Buspirone was recently found to antago-
nize D3 and D4 receptors with higher afﬁnity than D2 receptors
(Bergman et al., 2013). Therefore, we chose to use NAD 299, a high
afﬁnity 5-HT1A antagonist that is more selective than WAY-100635
(Johansson et al., 1997) but displays similar potency (Martin et al.,
1999), at a dose based on previous central administration studies
(Kehr et al., 2010; Ross et al., 1999). The complex receptor afﬁnity
proﬁle and the robust reproducible anxiogenic effects of buspirone
at an acute high dose level, merit investigation.
The nucleus incertus (NI), a cluster of GABAergic neurons in the
brainstem located at the ﬂoor of the fourth ventricle, is the prin-
cipal source of neuropeptide relaxin-3 in mammalian brain (Tanaka
et al., 2005) and richly coexpresses CRF1 (Ma et al., 2013; Tanaka
et al., 2005), 5-HT1A (Miyamoto et al., 2008) and D2 receptors
(Kumar et al., 2015). The NI is highly conserved in zebraﬁsh, lower
mammals such as rodents and cats, as well as in primates such as
monkeys and humans, illustrating its physiological relevance (Ma
et al., 2009). The NI/relaxin-3 system is reported to be involved in
several functions such as stress responses, arousal, anxiety, fear,
memory, cognition, feeding, reward and sleep (for reviews see:
Ryan et al., 2011; Smith et al., 2011). The NI is proximally located to
the raphe nuclei with robust bidirectional connections to the me-
dian raphe in particular, which could explain negative regulation of
relaxin-3 expression in the NI by 5-HT (Miyamoto et al., 2008).
Exposure to aversive environments and to anxiogenic compounds
such as FG 7142, activates relaxin-3 positive NI neurons and dorsal
raphe serotonergic neurons simultaneously, suggesting that these
interact to modulate physiological anxiety (Lawther et al., 2015).
The cognate relaxin-3 receptor, RXFP3, is highly expressed in areas
involved in anxiety, thus central administration of an agonist cau-
ses anxiolytic effects in the light-dark paradigm and elevated plus
maze (Ryan et al., 2013). The NI strongly responds to stressful
conditions such as swim stress, exposure to elevated platform, foot
shock stress byway of increasing Fos expression aswell as relaxin-3
mRNA levels (Li and Sawchenko, 1998; Rajkumar et al., 2016;
Tanaka et al., 2005). Interestingly, the NI is more strongly acti-
vated by escapable forms of stress that require high behavioural
activity rather than those that induce freezing (Goto et al., 2001;
Ryan et al., 2011; Timofeeva et al., 2003).The robust bidirectional
connections and common target regions of the NI, median raphe
and interpeduncular nucleus indicate that they may function as an
ascending control of behavioural activation (Goto et al., 2001).
It is generally well-accepted that at low doses, buspirone pref-
erentially acts on the raphe nuclei due to their large (pre-synaptic)
5-HT1A receptor reserve (Carli et al., 1989; Newman-Tancredi et al.,
1998). Thus in order to study the role of NI, which expresses post-
synaptic 5-HT1A receptors, in the neuropharmacology of buspirone,
a high dose is suitable. Buspirone is an anxio-selective drug, and
hence it is likely that the structures it modulates are part of thephysiological anxiety circuit (Eison and Temple, 1986). Anxiety is
characterized by increased arousal and behavioural inhibition, both
of which the NI/relaxin-3 system are involved in. The notable
expression of receptors and peptides in the NI, that are putative
targets for anxiety disorders (especially, 5-HT1A, D2, CRF and
relaxin-3), extensive and strategic connections of this small neuron
group to other brain structures that are known tomodulate anxiety,
arousal and theta activity (especially, median raphe, amygdala,
prefrontal cortex, bed nucleus of stria terminalis, medial septum
and hippocampus) lead us to hypothesize that the NI may be
involved in the anxiogenic effect of a high dose of buspirone.
A high dose of 3 mg/kg intraperitoneal (i.p.) dose of buspirone
with a pretreament time of 30 minwas selected based on literature
(Collinson and Dawson, 1997; Lim et al., 2008) and preliminary
studies where 3 doses (0.125 mg/kg, 1 mg/kg and 3 mg/kg) were
tested on 3 anxiety paradigms, namely the elevated plus maze, the
light-dark box and the open ﬁeld. Only the highest dose produced a
consistent anxiogenic response and was thus selected for further
study in context of the NI. In order to determine if this anxiogenic
dose activated the NI, c-Fos expression in the NI was quantiﬁed. To
further examine if the NI played a role in the anxiogenic effect of
the high dose of buspirone, the effect of NI lesioning on the drug
response was tested. To study the direct anxiety-modulating effects
of buspirone on the NI, intra-NI infusion of the drug was conducted.
Pharmacological interaction studies with a D2 agonist (quinpirole)/
5-HT1A antagonist (NAD 299) and buspirone were subsequently
carried out to determine the receptor systemmediating the effects.
2. Materials and methods
2.1. Animals
Male Sprague-Dawley rats (280e350 g), obtained from InVivos
Pte Ltd, Singapore, were utilised in this investigation. The pro-
cedures conducted were in compliance with the guidelines of the
National Institutes of Health Guide for Care and Use of Animals, and
with approval from the Institutional Animal Care and Use Com-
mittee of the National University of Singapore. Rats were housed in
individually ventilated cages, in a temperature controlled room
(22e24 C) with a 12 h light-dark cycle and given ad libitum access
to food and water.
2.2. Drugs and chemicals
Buspirone hydrochloride (Chemical name: 8-[4-[4-(2-
Pyrimidinyl)-1-pipirazinyl]butyl]-8-azaspiro[4,5]decane-7,9-dione
hydrochloride; Purity: >99%; Tocris Bioscience, Bristol UK), NAD
299 hydrochloride (Chemical Name: (3R)-3-(Dicyclobutylamino)-
8-ﬂuoro-3,4-dihydro-2H-1-benzopyran-5-carboxamide hydro-
chloride; Purity: >98%; Tocris Bioscience), quinpirole hydrochloride
(Chemical Name: (4aR-trans)-4,4a,5,6,7,8,8a,9-Octahydro-5-
propyl-1H-pyrazolo[3,4-g]quinoline hydrochloride; Purity: >98%;
Tocris Bioscience), ketamine (Parnell Manufacturing Pty Ltd., Syd-
ney, Australia), xylazine (Ilium Xylazil, Troy Laboratories Pty Ltd.,
New South Wales, Australia), enroﬂoxacin (Baytril 5%, Bayer
HealthCare, Leverkusen, Germany), and carprofen (Carprieve,
Norbrook Laboratories, Newry, Northern Ireland) were freshly
prepared in sterile isotonic (0.9%) saline (B. Braun, Melsungen,
Germany) before use. Pentobarbital (Valabarb) was purchased from
Jurox Pty Ltd., New South Wales, Australia.
2.3. Surgery
The rats were anaesthetised with a cocktail of ketamine and
xylazine and mounted onto a stereotaxic frame. The scalp was
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burr hole was drilled at AP: -9.7 mm,ML: 0 mm from the bregma to
target the NI (Paxinos and Watson, 2007). These coordinates have
been used to successfully target the NI in previous studies con-
ducted at our laboratory (Farooq et al., 2013, 2016; Kumar et al.,
2015; Lee et al., 2014; Rajkumar et al., 2016).
NI-CRF-saporin lesioning was recently established by our labo-
ratory and we showed that the CRF-saporin lesioning selectively
ablates CRF expressing cells resulting in signiﬁcantly lowered
expression of CRF1 receptors, relaxin-3, GAD65 and 5-HT1A re-
ceptors (Lee et al., 2014). Serotonin expression in the neighboring
dorsal raphe and CRF1 expression in the adjacent dorsal
tegmentum and locus coeruleus remained intact showing that the
lesioning technique only targets CRF1 expressing cells at the NI
coordinates (Lee et al., 2014). The surgery was conducted as
described (Lee et al., 2014). Brieﬂy, bilateral injections of 0.2 ml/site,
made 7.5 mmventral to the surface of the skull, delivered 86 ng/site
of CRF-saporin or blank saporin (Advanced targeting Systems, San
Diego, California, USA) over 5 min to cause NI or sham-lesioning,
respectively. The needle was left in place for 5 more minutes
before withdrawal. The scalp was sutured, and postoperative care
with subcutaneous injections of antibiotic (Baytril) and analgesic
(Carprofen) was conducted daily for the ﬁrst 5 days. The rats were
allowed a total rehabilitation period of 14 days before any experi-
ments were carried out.
Cannula implantation surgery targeting the NI was carried out
as previously described (Farooq et al., 2013; Kumar et al., 2015;
Rajkumar et al., 2016). Brieﬂy, a guide cannula (PlasticsOne, Roa-
noke, Virginia, USA) 8 mm in length was carefully inserted to a
depth of 7.4 mm from the skull surface and was held in place with
dental cement and anchoring screws ﬁtted to the skull. The rats
were allowed to rehabilitate for 1 week with the same post-
operative care schedule as described above.
2.4. Behavioural testing
Rats were acclimatized to the behaviour room for at least 1 h
before the experiments. For systemic buspirone experiments, the
rats were weighed and intraperitoneally injected with buspirone
(0.125 mg/kg, 1 mg/kg or 3 mg/kg dose) or vehicle (isotonic sterile
saline) in a volume of 1.0 ml/kg. Behavioural assessment began
after the pretreatment time of 30 min.
For the intra-NI experiments, buspirone (2.5 mg or 5 mg); NAD
299 (0.5 mg); quinpirole (1 mg) or vehicle (sterile isotonic saline)
were infused in a 0.1 ml volume. The doses of NAD 299 (Kehr et al.,
2010) and quinpirole are based on previous studies conducted
where micro-infusion of these drugs produced an experimental
effect indicating an efﬁcacious dose (Amato et al., 2012; Borowski
and Kokkinidis, 1996; Munro and Kokkinidis, 1997; Wan and
Swerdlow, 1993). The drug administration was conducted by
gently restraining the rat and inserting an infusion cannula (Plas-
ticsOne, USA), which had a 1mm projection from the guide cannula
connected to a plastic tubing. A 0.1 ml volume of the solution was
infused using a syringe (SGE Analytical Science, Trajan Scientiﬁc Pty
Ltd, Melbourne, Australia) connected to the plastic tubing over a
period of 30 s, after which the infusion cannula was left in place for
1 min before re-capping and placing the rat in the exploration
arenas. Behavioural testing began immediately.
Behavioural apparatus (as depicted in Fig. 1BeE) was cleaned
with 70% ethanol between the trials. All the behavioural observa-
tions were video recorded and analyzed using a video tracking
system (Ethovision, version XT10, Noldus, Wageningen,
Netherlands) except for the home-cage monitoring which was
monitored through the laboratory animal behaviour observation
registration and analysis system (LABORAS, Metris B.V., Hoofddorp,Netherlands). Elevated plus maze and light-dark box exploration
lasted for 5 min while the open ﬁeld paradigm was a 10 min trial.
The elevated plus maze and open ﬁeld test were conducted in dim
room lighting while in the light-dark box the light area was illu-
minated at 440 lux. The LABORAS home-cage monitoring was
conducted in normal lighting and behavioural parameters were
continuously assessed for 2 h by the LABORAS software. For the
elevated plus maze, light-dark exploration test and open ﬁeld
paradigm, the rat was placed in the central square facing an open
arm, against the wall in the light area and against the wall in the
periphery of the maze, respectively.
Motor coordination and sedation were assessed using an
accelerating rotarod (4e40 rpm over 5 min). The rats were given 2
training sessions and the following day they were placed on the
rotarod (Ugo Basile S. R. L., Monvalle VA, Italy) prior to dosing and
either directly after dosing for the intra-NI infusion experiments, or
after a pretreatment time of 30 min for the systemic buspirone
injection experiments (Hughes et al., 2013; Walker et al., 2001).
2.5. Post-mortem tissue processing
Cannula implanted rats were anaesthetised with an overdose of
pentobarbital and 0.1 ml of Pontamine sky blue dye was infused into
the NI via the guide cannula in the same manner as the drug
infusion described above. Subsequently, transcardial perfusionwith
isotonic saline followed by 4% paraformaldehyde in phosphate
buffer (0.1 M). The brains were post-ﬁxed in 4% paraformaldehyde
at 4 C followed by 30% sucrose. 30 mm sections were collected on
glass slides in a cryostat (CM 3050, Leica Microsystems, Wetzlar,
Germany) and allowed to air-dry before being studied under a light
microscope (BX-51, Olympus, Tokyo, Japan) to determine if the
tracks were in the NI. Rats with incorrect cannula positions were
excluded from analysis. Representative sections were Nissl stained
and imaged under the light microscope for illustration purposes
(Fig. 1A). NI CRF-saporin lesioning was conﬁrmed with post-
mortem Western blotting conducted as per Lee et al., 2014.
2.6. c-Fos immunoﬂuorescence and cell counting
Brieﬂy, naive rats housed in pairs were allowed to acclimatize
for at least 3 days in the vivarium before being transferred to the
experimental room (20e23 C, normal room lighting). The rats
received intraperitoneal injections of either buspirone (3 mg/kg) or
vehicle in a volume of 1.0 ml/kg and after a pretreatment time of
2 h, the rats were anesthetized with a pentobarbital overdose.
Transcardial perfusionwas carried out with isotonic saline followed
by 2% paraformaldehyde in phosphate buffer (0.1 M). The brains
were subsequently post-ﬁxed in 2% paraformaldehyde at 4 C for
2 h and soaked in 15% sucrose followed by 30% sucrose at 4 C for 2
days each. Free-ﬂoating sections (30 mm) were collected serially in
PBS in a cryostat (CM 3050, Leica Microsystems, Germany), blocked
in 5% goat serum in 1xPBS with Triton X; incubated in the primary
antibodies [anti-c-Fos (1:600; Calbiochem, Merck Millipore, Bill-
erica, Massachusetts, USA); anti-CRF-RI/II (1:400; Santa Cruz
Biotechnology, Inc., Dallas, Texas, USA))] diluted in blocking solu-
tion overnight at 4 C; followed by incubation in solutions con-
taining appropriate Alexa Fluor secondary antibodies (Invitrogen,
Life Technologies, Thermo Fisher Scientiﬁc, Waltham, Massachu-
setts, USA) for an hour at room temperature in the dark. The sec-
tions were rinsed, plated, covered with ProLong Gold Antifade
Mountant with DAPI (Thermo Fisher Scientiﬁc Inc., Waltham,
Massachusetts, USA) and imaged with ﬂuorescence microscope
(BX-51, Olympus, Japan). The sections were gently shaken during all
incubation periods including the rinses. The immunostaining pro-
cedures were conducted at 20e23 C under normal room lighting.
Fig. 1. (A) Representative images showing the cannula position in the nucleus incertus at 2x (A1; scale bar represents 1 mm) and 10x (A2, scale bar represents 200 mm)
magniﬁcation. Schematic diagram of the behavioural apparatus, the elevated plus maze (B), the light-dark box (C), the open ﬁeld (D), the LABORAS home-cage monitoring system
(E).
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at least 6 sections were stained per rat. The images were analyzed
with ImageJ (NIH, Maryland, USA). Based on the distribution of CRF
positive cells, a region of interest was created bilaterally on either
side of the fourth ventricle. The c-Fos positive cells within this re-
gion were quantiﬁed. c-Fos positive cells per unit area were
calculated for each rat and averaged for each treatment group.
Similar c-Fos immunoﬂuorescence and cell counting techniques
were established at our lab and conducted in several studies
(Rajkumar et al., 2013, 2016; Verma et al., 2007; Verma et al., 2006).2.7. Statistical analysis
All statistical analysis conducted, except for the rotarod assay,
were between-subjects. If there were more than 2 experimental
groups, one-way ANOVA with post hoc Bonferroni's test was con-
ducted. All the behavioural and c-Fos data with 2 experimental
groups were analyzedwith unpaired Student's t-tests except for the
rotarod assay, for which a paired t-test was conducted. All com-
parisons were made against the vehicle treatments. The behav-
ioural data from home-cage monitoring (LABORAS) at various time
points was subjected to repeated measures ANOVA across time
followed by multivariate analysis to identify the differences at
speciﬁc time points. GraphPad Prism Version 5.00 (GraphPad
Prism, La Jolla, California, USA) was used for the statistical analysis
and the level of statistical signiﬁcance was set at p < 0.05. The data
are expressed as mean ± SEM.3. Results
3.1. Effect of systemic buspirone on behavioural paradigms and c-
Fos expression
Buspirone (1 mg/kg and 3 mg/kg) induced an anxiogenic effect
on the elevated plus maze. One-way ANOVA on the data from theelevated plus maze showed that systemic buspirone signiﬁcantly
inﬂuenced percentage time spent in the open arms of the elevated
plus maze [F3, 53 ¼ 8.754, P < 0.0001]. Post hoc Bonferroni's tests
showed that buspirone at 1 mg/kg (P < 0.05) and 3 mg/kg
(P < 0.001) signiﬁcantly reduced percentage time spent in open
arms compared to the vehicle (Fig. 2A). There was no signiﬁcant
difference between treatment groups in the percentage of open
arm entries [F3, 53¼ 1.851, P¼ 0.149]. One-way ANOVA showed that
systemic buspirone signiﬁcantly inﬂuenced total number of closed
arm entries in the elevated plus maze [F3, 53 ¼ 3.624, P < 0.05]. Post
hoc Bonferroni's tests showed that there was no signiﬁcant differ-
ence between any of the doses of buspirone compared to the
vehicle (Fig. 2B) indicating that the buspirone treatment did not
affect locomotion.
In the light-dark box test, the highest dose of buspirone induced
anxiety. One-way ANOVA showed that systemic buspirone signiﬁ-
cantly inﬂuenced duration in the light area of the light-dark box [F3,
51 ¼ 8.293, P < 0.0001]. Post hoc Bonferroni's test showed that
buspirone at 3 mg/kg (P < 0.001) signiﬁcantly reduces percentage
time spent in the light area compared to the vehicle treatment
(Fig. 2C). One-way ANOVA showed that systemic buspirone inﬂu-
enced the number of transitions made in the light-dark box [F3,
51¼8.427, P < 0.0001]. Post hoc Bonferroni's tests showed that there
was no signiﬁcant difference between any of the doses of buspirone
compared to the vehicle (Fig. 2D).
The highest dose of buspirone tended to induce an anxiogenic
response on the open ﬁeld test based on the anxiety indices but also
reduced distance travelled, indicating a possible suppression of
locomotion effect. One-way ANOVA showed that buspirone (3 mg/
kg) dose signiﬁcantly inﬂuenced time spent in the centre [F3,
52 ¼ 4.141, P < 0.05], frequencies of entries to centre [F3, 52 ¼ 5.864,
P ¼ 0.0016] and distance travelled [F3, 52 ¼ 17.3, P < 0.0001] in the
open ﬁeld (Fig. 2EeG). Post hoc Bonferroni's test showed that
buspirone (3 mg/kg) signiﬁcantly (P < 0.05) reduced the time spent
in the centre (Fig. 2E), buspirone (1 and 3 mg/kg) signiﬁcantly
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respectively, Fig. 2F), reduced the distance travelled (P < 0.01 and
0.001, respectively, Fig. 2G) compared to the vehicle treatment.
Based on the anxiety paradigms conducted above, only the
highest dose of 3 mg/kg induced a consistent anxiogenic effect.
Therefore, this dose was tested on the subsequent experiments.
In the rotarod test, there was no signiﬁcant (P ¼ 0.428, two-
tailed paired t-test) difference in the pre- and post-buspirone fall
latency (Fig. 2H). This shows that buspirone treatment at the
highest dose did not affect motor coordination or sedation thus
lending credibility to its anxiogenic effects.
The number of c-Fos positive cells per unit area with the total
area being demarcated by CRF1 expressing cells were signiﬁcantly
increased (P < 0.001) in buspirone (3 mg/kg) treated rats compared
to vehicle-treated rats (Fig. 3C) indicating that the NI is activated
and may play a role in the anxiogenic effect induced by this dose of
buspirone.
In order to study the effect of buspirone treatment on NI-
lesioned rats, the baseline effect of lesioning the NI on anxiety
was examined. In the elevated plusmaze, the NI-lesioned rats spent
a shorter percentage of time in the open arms (P < 0.001) and had a
lower percentage of open arm entries (P < 0.05) compared to the
sham-lesioned animals (Fig. 4AeB). There was no signiﬁcant dif-
ference in the total closed arm entries (P ¼ 0.871; Fig. 4C). In the
study examining the effect of buspirone (3 mg/kg) on sham-
lesioned and NI-lesioned rats, the percentage time spent in the
open arms of the elevated plus maze (P < 0.01) and percentage of
open arm entries (P < 0.05) were signiﬁcantly increased in the NI-
lesioned rats compared to the sham-lesioned rats (Fig. 4DeE).
There was no signiﬁcant difference in the total closed arm entries
(P ¼ 0.826; Fig. 4F). Selective lesioning of the NI by CRF-saporin
attenuates the anxiogenic effect of buspirone thus drawing atten-
tion to the possible causal role of the NI in the robust elevation of
anxiety by a high dose of buspirone.
3.2. Effect of intra-NI buspirone on behavioural paradigms
Buspirone was directly infused into the NI at 2 doses, 2.5 mg and
5 mg, and its effect of the anxiety paradigms was measured. Two-
tailed unpaired t-tests were conducted on all the following data
unless otherwise speciﬁed. Buspirone (2.5 mg) infused into the NI
did not signiﬁcantly affect the percentage time spent in the open
arms (P ¼ 0.833) and the percentage of open arm entries
(P ¼ 0.946; Fig. S1).
Buspirone (5 mg) caused anxiogenic effects in rats when tested
on the elevated plus maze and open ﬁeld exploration paradigms. In
the elevated plus maze, the percentage time spent in open arms
(P < 0.01, Fig. 5A) was signiﬁcantly reduced in the buspirone-
treated group compared to the vehicle-treated group. However,
there was no signiﬁcant difference between treatment groups in
the percentage of open arm entries (P ¼ 0.928, Fig. 5B) and total
closed arm entries (P ¼ 0.358, Fig. S2) indicating that the locomo-
tion of the buspirone-treated rats was unaffected. In the open ﬁeld
paradigm, the time spent in the centre (P < 0.05, Fig. 5C), frequency
to enter the centre (P < 0.01, Fig. 5D) and distance travelled
(P < 0.05, Fig. 5F) were signiﬁcantly reduced and, the latency to
enter the centre (P < 0.01, Fig. 5E) and time spent in periphery
(P < 0.05, Fig. S3A) were signiﬁcantly increased in the buspirone
(5 mg)-treated group compared to the vehicle-treated group. The
frequency of entries to middle area was signiﬁcantly reduced in
buspirone (5 mg) treated rats compared to vehicle-treated rats
(P < 0.05; Fig. S3B).
In the home-cage activity (LABORAS) study, repeated measures
ANOVA on the data across time showed signiﬁcant changes in
distance travelled (F23,230 ¼ 16.67, P < 0.0001), time spent inlocomotion (F23,230 ¼ 15.63, P < 0.0001), time spent in immobility
(F23, 230 ¼ 5.75, P < 0.0001), time spent in rearing (F23,230 ¼ 17.02,
P < 0.0001), time spent in feeding (F23,230 ¼ 5.75, P < 0.0001) and
frequency of feeding (F23,230 ¼ 1.753, P < 0.05) (Fig. 6AeE, H). Time
spent in grooming (F23,230 ¼ 1.131, P ¼ 0.312) and drinking (F23,
230 ¼ 1.038, P ¼ 0.418) were not signiﬁcantly altered over time
(Fig. 6FeG). Intra-NI buspirone (5 mg) signiﬁcantly increased the
time spent in immobility (F1,10 ¼ 7.497, P < 0.05) and time spent in
feeding (F1,10 ¼ 7.497, P < 0.05) compared to saline infusion
(Fig. 6CeD). Other parameters, distance travelled (F1,10 ¼ 2.268,
P ¼ 0.163), time spent in locomotion (F1,10 ¼ 2.485, P ¼ 0.146),
feeding frequency (F1,10 ¼ 1.316, P ¼ 0.278), time spent in drinking
(F1, 10 ¼ 1.814, P ¼ 0.2078), time spent rearing (F1,10 ¼ 3.722,
P ¼ 0.0825) and time spent grooming (F1,10 ¼ 0.8075, P ¼ 0.39)
were not signiﬁcantly affected by intra-NI buspirone administra-
tion (Fig. 6AeB,EeH). Two-tailed unpaired t-tests conducted on the
2 h data indicated that the time spent in immobility (P < 0.05) was
signiﬁcantly increased in buspirone-treated rats (Fig. 6C. Inset
graph). All the other parameters: frequency of immobility (counts)
(P¼ 0.743), distance travelled (P¼ 0.163), time spent in locomotion
(P ¼ 0.14601), time spent in rearing (P ¼ 0.0825), frequency of
rearing (P ¼ 0.141), time spent in grooming (P ¼ 0.390), frequency
of grooming (P ¼ 0.235), time spent in feeding (P ¼ 0.290), fre-
quency of feeding (P ¼ 0.359), time spent in drinking (P ¼ 0.208)
and frequency of drinking (P ¼ 0.216) failed to attain statistical
signiﬁcance (some of these are illustrated in inset graphs of Fig. 6).
Despite the reduction in locomotion observed in the open ﬁeld, in a
home-cage enviroment, the time spent in locomotion and distance
travelled were unaffected by intra-NI buspirone (5 mg) thus indi-
cating that the latter does not affect locomotion per se.
3.3. Pharmacological interaction studies
The silent dose study for NAD 299 (0.5 mg) revealed that at this
dose the anxiety and locomotion parameters were unaffected. Two-
tailed unpaired t-test were conducted on all the following data.
Intra-NI administration of NAD 299 (0.5 mg) did not affect the
percentage time spent in the open arms of the elevated plus maze
(P ¼ 0.659, Fig. S4A) and the percentage of open arm entries
(P ¼ 0.234; data not shown). There were no signiﬁcant differences
in the time spent (P¼ 0.354) and frequency of entries (P¼ 0.279) in
the centre and middle area; and the distance travelled (P ¼ 0.545)
in the open ﬁeld (Fig. S4BeD) test. These data conﬁrm that NAD 299
(0.5 mg) did not alter baseline behaviour and therefore could be
utilised for the subsequent experiments.
In a cohort of rats treated with systemic buspirone (3 mg/kg),
the percentage time spent in open arms was signiﬁcantly (P < 0.05)
increased in the intra-NI NAD 299 (0.5 mg)-treated rats compared to
the vehicle-treated rats in the elevated plus maze (Fig. 7A). There
was no signiﬁcant difference between the treatment groups in the
percentage of open arm entries (P ¼ 0.191) (data not shown) and
the total closed arm entries (P ¼ 0.361) (Fig. 7B). In the cohort of
rats treated with systemic buspirone (3mg/kg), the total time spent
in the centre and middle area (P < 0.05) and frequency of entries to
centre and middle area (P < 0.05) were signiﬁcantly increased in
the intra-NI NAD 299 (0.5 mg) treated rats compared to the vehicle-
treated rats in the open ﬁeld test (Fig. 7CeD). There was no sig-
niﬁcant difference between the treatment groups in the latency to
enter centre (P ¼ 0.984) (data not shown) and distance travelled
(P ¼ 0.520) (Fig. 7E).
In the pharmacological interaction study with buspirone (3 mg/
kg, i.p.) and quinpirole (1 mg, intra-NI infusion), the percentage time
spent in the open arms (P ¼ 0.344) and the percentage of open arm
entries (P ¼ 0.676) in the elevated plus maze were unaffected
(Fig. S5AeB). Similarly, there was no signiﬁcant difference in the
Fig. 2. Effect of systemic buspirone (BUS) on the EPM, LDB, open ﬁeld and rotarod assay. Different doses (0.125 mg/kg; 1 mg/kg; 3 mg/kg) of buspirone were tested in anxiety
paradigms (AeE) while only the 3 mg/kg dose was tested in the rotarod (H). (A) Percentage time spent in the open arms (OA) in the EPM. n ¼ 16 (vehicle) n ¼ 18 (buspirone
0.125 mg/kg) n ¼ 5 (buspirone 1 mg/kg) n ¼ 18 (buspirone 3 mg/kg). (B) Total entries into the closed arms in the EPM. n ¼ 16 (vehicle) n ¼ 18 (buspirone 0.125 mg/kg) n ¼ 5
(buspirone 1 mg/kg) n ¼ 18 (buspirone 3 mg/kg). (C) Duration in the bright area of the light-dark box. n ¼ 17 (vehicle) n ¼ 17 (buspirone 0.125 mg/kg) n ¼ 5 (buspirone 1 mg/kg)
n ¼ 16 (buspirone 3 mg/kg). (D) Number of transitions in the light-dark box. n ¼ 17 (vehicle) n ¼ 17 (buspirone 0.125 mg/kg) n ¼ 5 (buspirone 1 mg/kg) n ¼ 16 (buspirone 3 mg/kg).
(EeG) Time spent in the centre, the frequency of entries to the centre and the distance travelled in the open ﬁeld, respectively. n ¼ 16 (vehicle) n ¼ 18 (buspirone 0.125 mg/kg) n ¼ 5
(buspirone 1 mg/kg) n ¼ 17 (buspirone 3 mg/kg). (H) Fall latency before and after buspirone (BUS; 3 mg/kg) treatment in the rotarod assay. n ¼ 13. For (AeG) One-way ANOVA
followed by post hoc Bonferroni's test. For (H) paired t-test. *p < 0.05 **p < 0.01 ***p < 0.001. Data represented as mean ± SEM.
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(P ¼ 0.580) and frequency of entries in the centre (P ¼ 0.625) and
distance travelled (P ¼ 0.187) in the open ﬁeld between thetreatment groups (Fig. S5CeF).
Thus intra-NI infusion of NAD 299 (0.5 mg) but not quinpirole
(1 mg), attenuated the anxiogenic effect of buspirone (3 mg/kg) on
Fig. 3. Effect of buspirone (BUS, 3 mg/kg) on Fos protein levels in the NI cells. (AeB) Representative ﬂuorescence images of vehicle treatment (A) and buspirone treatment (B). The
CRF1/2 expressing cells demarcate the region of interest (A, B). Buspirone (3 mg/kg) treatment increased the number of cells expressing Fos protein (A0 , B0). The dotted lines indicate
the fourth ventricle that serves as a landmark. Scale bars: 200 mm. (C) Number of Fos positive cells per unit area in the NI. n ¼ 6 (Vehicle) n ¼ 6 (Buspirone). Students' t-test
***p < 0.001. Data represented as mean ± SEM.
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In the present study, systemic buspirone (3 mg/kg) produced
signiﬁcant anxiogenic effects on all three anxiety paradigms tested
(elevated plus maze, light-dark and open ﬁeld exploration). This
supports a wealth of preclinical literature on buspirone that reveals
an anxiogenic effect after an acute high dose (Belzung et al., 2001;
Collinson and Dawson, 1997; Dekeyne et al., 2000; Hascoet et al.,
2000; Hestermann et al., 2014; Leong et al., 2012; Moser, 1989).
Although the rats treated with buspirone (3 mg/kg) travelled a
shorter distance in the open ﬁeld, the locomotor indices in the
elevated plus maze (total closed arm entries) and rotarod perfor-
mance were unaffected. The rotarod assay tests for ataxia, which
could result from impairments in gait, posture, motor coordination,
motor learning, sedation and intoxication and is frequently used to
study the sedative effects of anxiolytics such as benzodiazepines
(Jones and Roberts, 1968; Martin et al., 1993; Monville et al., 2006).Further, only a marginal decrease in locomotion was previously
reported with 3 mg/kg of buspirone (Leveleki et al., 2006). How-
ever, there are other methods that could detect subtle ambulatory
changes such as gait analysis which could be used in future studies.
The reduction in locomotion in the anxiety paradigms could be a
result of fear or anxiety which can induce behavioural inhibition,
reducing exploration and inhibiting ongoing activity (Gray and
McNaughton, 2003; Weiss et al., 1998).
Based on the aforementioned experiments, only the highest
(3 mg/kg) dose of buspirone produced a marked anxiogenic effect
consistent across the three paradigms and this dose was therefore
selected for the subsequent experiments. Systemic administration
of the selected anxiogenic dose of buspirone was found to signiﬁ-
cantly increase c-Fos expression in the NI neurons within the re-
gion of interest based on the CRF1 receptor expression, a marker
frequently used to delineate the cytoarchitecture of the NI
(Rajkumar et al., 2013, 2016; Tanaka et al., 2005). Increased c-Fos
expression is taken as a measure of NI activation as basal c-Fos
expression in the NI is minimal (Cullinan et al., 1995; Herdegen
Fig. 4. (AeC) Effect of NI lesioning on rats tested in the EPM. (A) Percentage time spent in the open arms. (B) Percentage of entries into the open arms. (C) Total entries into the
closed arms. n ¼ 9 (Sham-lesioned) n ¼ 9 (NI-lesioned). (DeF) Effect of systemic buspirone (BUS; 3 mg/kg) on sham- and NI-lesioned rats tested on the EPM. (D) Percentage time
spent in the open arms. (E) Percentage of entries into the open arms. (F) Total entries into the closed arms. n ¼ 10 (Sham þ buspirone) n ¼ 6 (NI-Lesion þ buspirone). Unpaired t-
test. *p < 0.05 **p < 0.01. ***p < 0.0001 Data represented as mean ± SEM.
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vehicle-treated rats in this study. While D2 receptor activation
usually induces Fos production, activation of 5-HT1A receptors
differentially induces c-Fos expression depending upon the brain
region (Missale et al., 1998; Peroutka, 1988). One study shows that
5-HT1A activation in the frontal cortex, hippocampus and cere-
bellum increases c-Fos expression albeit at different time points,
however, c-Fos expression in the striatum is unaltered, despite all of
these regions having post-synaptic 5-HT1A receptors (since they do
not express 5-HT) (Tilakaratne and Friedman, 1996). Similarly,several studies show that 5-HT1A receptor activation stimulates
adenylate cyclase activity, thus increasing cAMP levels and in turn
c-Fos expression particularly in the hippocampus (Buritova et al.,
2003; Cadogan et al., 1994; Lucas et al., 1993; Markstein et al.,
1986; Sassone-Corsi et al., 1988; Sijbesma et al., 1991). But on the
other hand, some studies indicate a negative correlation of activa-
tion of 5-HT1A and adenylate cyclase activity (Bockaert et al., 1987;
De Vivo and Maayani, 1986; Hoyer and Schoeffter, 1991; Peroutka,
1988; Weiss et al., 1986). Pre-synaptic 5-HT1A receptors in the
raphe nuclei when activated by 8-OH-DPAT attenuated the c-Fos
Fig. 5. Effect of intra-NI buspirone (BUS; 5 mg) on the EPM and open ﬁeld. (A) Percentage time spent in the open arms in the EPM. (B) Percentage of open arm entries in the EPM.
n ¼ 6 (Vehicle) n ¼ 7 (Buspirone). (CeF) Duration in the centre, the frequency of entries to the centre, the latency to enter the centre and the distance travelled in the open ﬁeld,
respectively. n ¼ 5 (Vehicle) n ¼ 6 (Buspirone). Unpaired t-test *p < 0.05 **p < 0.01. Data represented as mean ± SEM.
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may be speculated that the c-Fos induced in the NI by buspirone, a
partial agonist at 5-HT1A receptors is via activation of the 5-HT1A
receptors in the NI, similar to the hippocampus, where activation of
the post-synaptic 5-HT1A receptors increases c-Fos (Tilakaratne and
Friedman, 1996).
However, the role of D2 receptors cannot be completely ruled-
out since it has been previously demonstrated in our laboratory
that systemic treatment with antipsychotics (which are D2antagonists) induces c-Fos in the NI (Rajkumar et al., 2013). These
effects may also be secondary to buspirone-mediated modulation
of other brain areas, such as the raphe nuclei that project strongly
to the NI. Indeed other studies have shown that the modulation of
the HPA axis by 5-HT1A agonists trans-synaptically altered c-Fos
expression in other brain regions (Compaan et al., 1996). It would
be of interest to study the effect of an anxiolytic dose of buspirone
on c-Fos expression in the NI as it would allow us to examine if the
NI plays in both opposing anxiety-modulating responses or just the
Fig. 6. Effect of intra-NI buspirone (BUS; 5 mg) on the LABORAS home-cage activity. Data points represent the mean of the parameter over the preceding 5 min (AeH). Columns
represent mean of values over 2 h and error bars represent SEM (insets in AeH). n ¼ 6 (vehicle) n ¼ 6 (buspirone). Repeated measures ANOVA followed by multivariate analysis.
*p < 0.05.
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Having shown that the anxiogenic dose of buspirone activates
NI, we examined whether the NI is necessary for the anxiogenic
effect. CRF-saporin lesioning of the NI, speciﬁcally ablates the CRF1
expressing NI neurons signiﬁcantly reducing CRF1, relaxin-3, GAD
65 and 5-HT1A expression levels (Lee et al., 2014). Lesioning the NI
resulted in an anxiogenic effect illustrated by reduced time spent
and entries into the open arms of the elevated plusmaze. Buspirone
(3 mg/kg) was tested on NI-lesioned rats in the elevated plus mazeparadigm. The anxiogenic effect of systemic buspirone was abol-
ished in the NI- lesioned rats but preserved in the sham-lesioned
rats with no signiﬁcant differences in locomotion. The present
data suggests that the NI is involved in mediating the anxiogenic
response of buspirone.
To examine whether the observed anxiogenic effects were due
to a direct action of buspirone on the NI or an indirect action via a
secondary structure that modulates the NI, buspirone was infused
directly into the NI. A signiﬁcant anxiogenic response is seen in the
Fig. 7. Effect of intra-NI NAD 299 (0.5 mg) in rats treated with systemic buspirone (3 mg/kg) on the EPM and open ﬁeld. (AeB) Percentage time spent in the open arms of the EPM
and total entries into the closed arm respectively. n ¼ 6 (Vehicle) n ¼ 6 (NAD 299). (BeD) Total time spent in the centre and middle, total frequency of entries to the centre and
middle and distance travelled in the open ﬁeld, respectively. n ¼ 6 (Vehicle) n ¼ 5 (NAD 299). Students' t-test *p < 0.05. Data represented as mean ± SEM.
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points to the idea that a direct action of buspirone on the NI con-
tributes to the anxiogenic effects. No signiﬁcant differences were
detected in the anxiety parameters of the light-dark box, indicating
that the anxiogenic effect was mild. Preliminary studies conducted
with a 2.5 mg dose administered to the NI did not show an anxio-
genic response indicating that the effect may be dose-dependent.
Intra-NI infusion of buspirone signiﬁcantly reduced the distancetravelled in the open ﬁeld. However, the locomotor indices in the
elevated plus maze, namely the total closed arm entries were not
altered by buspirone. To determine if intra-NI buspirone altered
locomotion per se, the buspirone infused rats were assessed in the
LABORAS home-cage monitoring system. The anxiogenic dose of
intra-NI buspirone did not affect distance travelled, the time spent
in locomotion, the frequency of feeding, time spent drinking, time
spent grooming and time spent rearing in LABORAS. The time spent
J.R. Kumar et al. / Neuropharmacology 110 (2016) 1e1412in immobility was lower in the buspirone-treated rats over the
entire 2 h period. However, the repeated measures ANOVA indi-
cated that the difference between treatments was only observed at
the 105 min bin, a time point at which a signiﬁcant increase in the
feeding was observed, which could explain the reduction in
immobility. No signiﬁcant differences were found in any of the
parameters during the ﬁrst 10 min, the time period representing
the immediate action of infused buspirone in the NI. Further, this
observation indicates that intra-NI buspirone treatment may not
affect the behaviour in a low stress home-cage environment. On the
other hand, the higher-stress paradigms, namely elevated plus
maze and open ﬁeld exploration, involve risk analysis (that might
involve NI) and thus buspirone induces behavioural inhibition
(Goto et al., 2001; McNaughton and Gray, 2000; Ryan et al., 2011;
Walf and Frye, 2007). As mentioned earlier, the NI has been
shown to be strongly activated by stressors while being minimally
active under basal conditions (Cullinan et al., 1995; Herdegen et al.,
1995; Herrera and Robertson, 1996). The reduction in the distance
travelled observed in the open ﬁeld is likely to be due to the in-
crease in anxiety level rather thanmotor impairment or sedation as
the distance travelled in the LABORAS home-cage system was un-
affected (Gray and McNaughton, 2003; Weiss et al., 1998).
While the aforementioned observations indicate that the NI is a
target of buspirone, pharmacological studies were conducted to
determine if 5-HT1A or D2 receptors were involved. Opposing the D2
receptor antagonism by buspirone, with quinpirole, a D2 agonist,
resulted in no signiﬁcant difference in the elevated plus maze,
light-dark box and open ﬁeld exploration. These results indicate
that the D2 receptors in the NI may not be directly involved in the
anxiogenic effects of buspirone. To examine the effects of 5-HT1A
receptors, intra-NI infusion of NAD 299, a selective antagonist of 5-
HT1A receptors was carried out and the behavioural changes in
elevated plus maze and open ﬁeld paradigms were studied. A study
was conducted initially to ensure that intra-NI NAD 299 at 0.5 mg
administered alone, did not alter any anxiety or locomotor pa-
rameters. Since NAD 299 is an antagonist, it is important to mea-
sure if there is a 5-HT basal tone in the NI which would induce any
behavioural effect when blocked. At the 0.5 mg dose, the relevant
parameters were unaffected.
In the systemic buspirone and intra-NI NAD 299 pharmacolog-
ical interaction study, compared to the intra-NI saline treated
controls, intra-NI NAD 299 treated rats spent signiﬁcantly more
time in the open arms of the elevated plus maze. Likewise, rats
treated with NAD 299, spent more time in and had a larger number
of entries to the centre and middle of the open ﬁeld with no effect
on locomotor indices such as total closed arm entries in the
elevated plus maze and distance travelled in the open ﬁeld. These
results demonstrate that 5-HT1A inhibition, attenuated the anxio-
genic response induced by systemic buspirone (3 mg/kg). Overall,
the observations from this behavioural study, indicate that 5-HT1A
receptors expressed in the NI are centrally involved in mediating
the anxiogenic response of a high dose of buspirone. Since bus-
pirone is an anxio-selective drug, it is likely that structures involved
in its mechanism of action are part of the physiological anxiety
circuit (Riblet et al., 1983; Temple et al., 1982). Therefore, the 5HT1A
receptors in the NI may be important in the expression and mod-
ulation of anxiety. It has been shown that these receptors are co-
expressed with relaxin-3 and may be instrumental in the nega-
tive regulation of relaxin-3 expression by serotonin signalling
(Miyamoto et al., 2008). The nature and pattern of these 5-HT1A
receptors should be studied in greater detail. The role of 5-HT1A
receptors in anxiety has been widely studied due to the biphasic
effects of 5-HT1A ligands and conﬂicting results in different tests of
anxiety (Celada et al., 2013; De Vry, 1995). It has been convincingly
shown that the anxiolytic effect of buspirone is mediated via the 5-HT1A autoreceptors in the raphe nuclei (Carli et al., 1989; File et al.,
1996). To date most studies have considered post-synaptic 5-HT1A
in the hippocampus as the main target due to its high receptor
density (Pazos et al., 1987). Infusion of buspirone into the hippo-
campus, produced an anxiolytic effect making it an unlikely target
for the anxiogenic effect observed at high doses (Kostowski et al.,
1989).
It is interesting to note a contrasting effect between the anxio-
genic effect of NI lesioning and buspirone treatment. Lesioning of
the NI produces an anxiogenic effect indicating that the NI reduces
anxiety physiologically, however buspirone's action on the NI in-
creases anxiety. CRF-saporin lesioning of the NI is a chronic pro-
cedure that ablates the NI cells over a period of 14 days and has
been shown to reduce relaxin-3 expression in the target regions
such as the medial septum (Lee et al., 2014). Studies involving
central infusion of RXFP3 selective ligands have indicated that
global relaxin-3 signalling is anxiolytic (Nakazawa et al., 2013; Ryan
et al., 2013). Thus lesioning the NI likely reduces relaxin-3 signal-
ling in target regions increasing baseline anxiety. Buspirone (3 mg/
kg) treatment on the other hand, is an acute procedure that, based
on the present study, stimulates the 5-HT1A receptors in the NI
producing an anxiogenic effect. When the NI is lesioned and these
receptors are reduced, the anxiogenic effect of buspirone is atten-
uated. The NI releases GABA, relaxin-3 and glutamate and responds
to a variety of neurotransmitters and thus is likely to modulate
anxiety levels differentially based on its level of activation and the
type of neurotransmitter signalling.
Although there is a lack of detailed clinical literature on the
direct anxiogenic effects associated with acute buspirone treat-
ment, several reports show that patients treated with buspirone
initially experience akathisia (a syndrome characterized by motor
restlessness, feeling of muscular quivering and inability to sit still),
jitteriness and panic (Brody et al., 1990; Chignon and Lepine, 1989;
Liegghio et al., 1988; Patterson,1988; Pohl et al., 1989; Sinclair et al.,
2009). In order to understand the neuropharmacology of buspir-
one, it is important to establish the target structures buspirone acts
on and the nature of this interaction. Actions in the NI could play a
role in the delayed efﬁcacy and side effects of buspirone. Future
studies should examine the role of the NI/relaxin-3 system in a
chronic buspirone regimen in rodents, while on the clinical side,
more information should be obtained regarding the acute effects of
buspirone during the initial phase of the treatment.
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